Factsheet

Manulife Global Fund - Asia Innovation Fund[##]

Investment Objective

The Fund aims to provide long-term capital growth for investors who hold a long term investment view and are prepared to accept significant fluctuations in the value of their investments, by investing primarily in equity and equity related securities of innovation and/or technology companies which are incorporated, located or listed, or have significant business interests, in the Asia Pacific region.


Fund Information

Fund Size	USD 93.51 million
Base Currency	USD
Dealing Frequency	Daily

Benchmark[**]
No representative benchmark

Investment Manager
Manulife Investment Management (Hong Kong) Limited

Fund Performance[‡‡]



Returns (%)[*]

	1 month	3 months	Year-to-Date	1 year	3 years	5 years	Since Inception	Calendar Year 2025	2024	2023	2022	2021
Class AA												
Fund (NAV to NAV)	3.99	-8.93	22.30	23.54	13.01	4.41	7.60	13.86	-4.06	18.92	-24.32	16.62
Fund (Offer to Bid)	-1.21	-13.48	16.18	17.36	11.10	3.35	7.33	8.17	-8.86	12.98	-28.11	10.79

Fund Characteristics[^]

Sector Allocation	%
Information Technology	56.34
Industrials	20.25
Healthcare	9.79
Materials	5.91
Consumer Discretionary	2.97
Communication Services	0.56
Cash & Cash Equivalents	4.18

Geographical Allocation	%
South Korea	36.83
Taiwan	25.88
China	13.97
India	8.78
Japan	7.71
Malaysia	1.57
Singapore	1.08
Cash & Cash Equivalents	4.18

Top Holdings	%
SAMSUNG ELECTRONICS CO., LTD.	5.09
SK HYNIX INC.	4.33
KINIK CO.	4.00
PHARMAESSENTIA CORP.	3.76
CHROMA ATE INC.	3.19
STERLITE TECHNOLOGIES LIMITED	3.19
PSK INC	2.86
ADITYA INFOTECH LIMITED	2.82
TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD.	2.80
DOOSAN FUEL CELL CO., LTD.	2.62

[##] Due to the change of the investment objective and policy of the Fund, the Fund has been renamed from Asian Small Cap Equity Fund to Asia Innovation Fund with effect from 10 July 2026. The performance data prior to 10 July 2026 was achieved under circumstances that no longer apply. Please refer to the offering document for details.

[**] With effect from 10 July 2026, the Fund does not compare its performance against nor is it managed in reference to any benchmark. It may freely select the securities in which it will invest.

[*] Performance figures are calculated with all dividends and distributions reinvested, taking into account all charges which would have been payable upon such reinvestment, and are annualised for periods over one year. The Offer to Bid performance includes the effect of an assumed current maximum front end load, which the investor might or might not pay. NAV to NAV figures reflect the Fund's investment performance.

[‡‡] With effect from 16 June 2014, the performance fee has been removed.

[^] Figures may not sum to 100 due to rounding. Information shown is for MGF-ASCEF.

Source: Manulife Investment Management (Hong Kong) Limited.

Manulife Global Fund - Asia Innovation Fund##

Class Information

Class	Currency	NAV Per Unit	Bloomberg Ticker	ISIN Code	Inception Date	Subscription Method
AA	USD	USD 3.762	MGASCEF LX	LU0274383008	30 Nov 2006	Cash

Class	Minimum Initial Investment	Management Fee (%,p.a.)	Distribution Frequency	Dividend per Unit	Ex-Dividend Date	Annualized Yield (%)
AA	USD 1,000	1.50	Annual	N.A.	N.A.	N.A.

Historical dividend yield is not indicative of future dividend payouts. Please refer to our website for more details.

Important Information

Manulife Global Fund (the “Company”) is an open-ended investment company registered in the Grand Duchy of Luxembourg. The Manulife Global Fund - Asia Innovation Fund ("the Fund") is recognised under the Securities and Futures Act of Singapore for retail distribution. The Company has appointed Manulife Investment Management (Singapore) Pte. Ltd. as its Singapore Representative and agent for service of process in Singapore.

The information provided herein does not constitute financial advice, an offer or recommendation with respect to the Fund. The information and views expressed herein are those of Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G) and its affiliates **(“Manulife”)** as of date of this document and are subject to change based on market and other conditions. Manulife expressly disclaims any responsibility for the accuracy and completeness of, and the requirement to update, such information.

Investments in the Fund are not deposits in, guaranteed or insured by Manulife and involve risks. The value of units in the Fund and any income accruing to it may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. Opinions, forecasts and estimates on the economy, financial markets or economic trends of the markets mentioned herein are not necessarily indicative of the future or likely performance of the Fund. **The Fund may use financial derivative instruments for the purposes of investment, efficient portfolio management and/or hedging.**

Investors should read the Singapore prospectus and the product highlights sheet and seek financial advice before deciding whether to purchase units in the Fund. A copy of the Singapore prospectus and the product highlights sheet can be obtained from Manulife or its distributors. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund is suitable for him.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.